| ²é¿´: 164 | »Ø¸´: 1 | |||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | |||
rzhmin½ð³æ (ÕýʽдÊÖ)
|
[½»Á÷]
ÇóÎÄÏ×
|
||
|
¡¸13] Kadota T, et al. Cefepine(diHCl/L-arginne blend):intravenous continuous infusion and/or single dose subcutaneous toxicity study in rats and dogs. Jpn J Antibiot. 1992:45 (6);612-617 [14] Kadota T, et al. Cefepime (BMYÒ»28142 diHCl/L-arginine blend) ne-month repeated dose subcutaneous toxicity study in rats.Jpn J Antibiot 1992;45 (6):620-41 [15]Kai S,et al. Reproductive and developmental toxicity studies on cefepime dihydrochloride administered subcutaneously to rats during the premating,gestation and lactation periods. Jpn J Antibiot 1992 Jun;45(6):642-60 [16]Kawano S,et al. Immunological properties of BMY-28100 and cefepime. Jpn J Antibiot 1990;43(7):1275Ò»88 [17]Brindley CJ, et al. Dose-proportional pharmacokinetics of cefepime in rats. Eur J Drub Metab Pharmacokinet 1991;3:9-14 [18]Nakanomyo H,et al. Study on the pharmacokinetics of cefepime (II). Jpn J Antibiot 1992;45(8):938-42 [19]Stampley AR, et al. Serum concentrations of cefepime (BMY-28142)£¬broad-spectrum cephalosporin, in dogs. Cornell Vet 1992;82 (1):69-77 |
» ²ÂÄãϲ»¶
288Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
281Çóµ÷¼Á£¨0805£©
ÒѾÓÐ19È˻ظ´
²ÄÁÏ¿¼Ñе÷¼Á
ÒѾÓÐ3È˻ظ´
346Çóµ÷¼Á[0856]
ÒѾÓÐ6È˻ظ´
294Çóµ÷¼Á²ÄÁÏÓ뻯¹¤×¨Ë¶
ÒѾÓÐ9È˻ظ´
328Çóµ÷¼Á£¬Ó¢ÓïÁù¼¶551£¬ÓпÆÑоÀú
ÒѾÓÐ12È˻ظ´
Ò»Ö¾Ô¸Î÷°²½»Í¨´óѧ²ÄÁϹ¤³Ìרҵ 282·ÖÇóµ÷¼Á
ÒѾÓÐ5È˻ظ´
085601²ÄÁϹ¤³Ìר˶Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
321Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
Ò»Ö¾Ô¸Öк£Ñó²ÄÁϹ¤³Ìר˶330·ÖÇóµ÷¼Á
ÒѾÓÐ7È˻ظ´
xbhchina
ľ³æ (Ö°Òµ×÷¼Ò)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 0.2
- Ìû×Ó: 3319
- ÔÚÏß: 22·ÖÖÓ
- ³æºÅ: 445839
- ×¢²á: 2007-10-28
- ÐÔ±ð: GG
- רҵ: ATRP&Chromatographing

2Â¥2009-06-01 18:36:12













ne-month repeated dose subcutaneous toxicity study in rats.
»Ø¸´´ËÂ¥